BioNTech, the German biotech group behind the first approved Covid-19 vaccine, warned there was “no data” to support moves to delay the second dose of the jab with the aim of reaching as many people as possible with limited supplies.
Germany is considering following the UK in delaying second doses amid growing concern over a more infectious variant of the virus, which emerged in England.
Germany’s health ministry confirmed to the Financial Times that it had asked the country’s vaccination commission “to review and evaluate the available data and studies and to issue a recommendation on this issue”.
您已閱讀12%（603字），剩餘88%（4231字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。